Blockchain Registration Transaction Record

NanoViricides to Present at NIBA Conference, Advancing Broad-Spectrum Antiviral NV-387

NanoViricides to present at NIBA 153rd Investment Conference on Oct 7, 2026. Lead drug NV-387 in Phase 2 trials for Ebola and Mpox, with plans for measles and other viruses.

NanoViricides’ presentation at the NIBA Investment Conference comes at a critical time when the world needs broad-spectrum antivirals that can address multiple viral threats, from Ebola and Mpox to measles and respiratory infections. The company’s lead candidate, NV-387, is already in Phase 2 trials for Ebola Bundibugyo and Mpox in the Democratic Republic of Congo, and its planned expansion into measles—backed by FDA Orphan Drug and Rare Pediatric Disease designations—highlights the potential of a single drug to combat several high-consequence diseases. If successful, this platform could simplify treatment and stockpiling strategies for outbreaks, especially in resource-limited settings. For investors, the conference provides an opportunity to gauge the progress of a clinical-stage biotech with a diverse pipeline and a unique nanomedicine approach. The outcomes of these trials and the company’s ability to advance NV-387 will be closely watched, as they could reshape how we respond to viral epidemics and pandemics.